GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Medicine

More

  • There's more to Merck's Ebola vaccine than money Friday, 31 Jul 2015 | 2:18 PM ET
    A file photo of an Ebola vaccine trial in Liberia last February.

    A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?

  • LONDON, July 31- Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics proving 100 percent effective in a trial in Guinea. In the event, it proved about as safe as a flu vaccine, said University of Reading virologist Ben Neuman, but it was still not given to children or...

  • LONDON— An experimental Ebola vaccine tested on thousands of people in Guinea seems to work and might help shut down the waning epidemic in West Africa, according to interim results from a study published Friday. There is currently no licensed treatment or vaccine for Ebola, which has so far killed more than 11,000 people in West Africa since the world's biggest...

  • July 30- Amgen Inc on Thursday reported higher-than-expected second-quarter profit and revenue, helped by strong sales of its Enbrel rheumatoid arthritis drug and cost cutting, and the company raised its full-year forecasts. Excluding special items, Amgen earned $2.57 per share, topping analysts' average expectations by 14 cents, according to Thomson...

  • Brilinta? Brintellix? FDA warns of drug name mix-ups Thursday, 30 Jul 2015 | 1:28 PM ET

    NEW YORK— The Food and Drug Administration said Thursday that some doctors and pharmacies are getting confused by the similar names of an antidepressant and a blood-thinning medicine. The FDA says it's not aware of any patients who took the wrong drug, but the agency says it has received 50 reports of medication errors, including cases where doctors prescribed...

  • UPDATE 1-Sanofi's diabetes sales slow, Genzyme's jump Thursday, 30 Jul 2015 | 4:54 AM ET

    PARIS, July 30- Sanofi reported lower second quarter sales for its strategic diabetes division on Thursday, hurt by continued pricing pressure in the United States, but it's biotech arm Genzyme recorded another quarter of double-digit growth, enabling the French drugmaker to beat forecasts overall. Forced to agree to increased rebates to maintain market...

  • Drug firm AstraZeneca reports slide in earnings Thursday, 30 Jul 2015 | 4:02 AM ET

    LONDON— Anglo-Swedish drug firm AstraZeneca says second-quarter net income fell 12 percent to $697 million as competition from generic drug companies reduced sales. CEO Pascal Soriot says the company made "good progress" in the period, with cost reductions supporting investment in science. Soriot also highlighted progress in the company's oncology...

  • Correction: Weight Loss-Balloon story Wednesday, 29 Jul 2015 | 1:55 PM ET

    FDA approves stomach-filling balloon for weight loss. FDA approves medical balloon to treat obesity by filling up stomach. Patients are sedated during the procedure, which takes less than 30 minutes, according to an FDA release.

  • *HIV sales help offset margin slide post Novartis deal. LONDON, July 29- GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts. The drugmaker recently sold its marketed cancer drugs to Novartis...

  • July 28- Gilead Sciences Inc said on Tuesday sales of its hepatitis C drugs hit a record of nearly $5 billion, surpassing Wall Street estimates as strong demand offset pricing pressures and restrictions on patient use from U.S. health insurers. Excluding items, Gilead earned $3.15 a share in the second quarter, beating the $2.71 average forecast by Wall Street...

  • Gilead posts huge beat on earnings and revenue Tuesday, 28 Jul 2015 | 5:28 PM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.

  • FDA approves stomach-filling balloon for weight loss Tuesday, 28 Jul 2015 | 5:24 PM ET

    Patients are sedated during the procedure, which takes less than 30 minutes, according to an FDA release. The FDA previously approved another balloon device for weight loss but it was withdrawn in 1992 due to a safety issue in which the balloon could rupture and block patients' arteries. "The new device aims to address the design failings of the earlier device," said...

  • DES MOINES, Iowa— The U.S. government expects to spend $191 million to pay chicken and turkey farmers for birds lost to avian flu, Agriculture Secretary Tom Vilsack said Tuesday as he called for Congress to consider a disaster program for poultry producers similar to that for other livestock farmers. Iowa, Minnesota and Missouri lost the most birds.

  • LONDON, July 28- Researchers in the United States trying to develop a vaccine against the deadly Middle East Respiratory Syndrome virus say they have had early signs of success in animal experiments. MERS, which causes coughing and fever and can lead to fatal pneumonia and kidney failure, has been reported mainly in Saudi Arabia and South Korea but has also been...

  • SAN FRANCISCO— Jody Kearns doesn't like to spend time obsessing about her Parkinson's disease. The 56- year-old dietitian from Syracuse, New York, had to give up bicycling because the disorder affected her balance. More than 75,000 people have enrolled in health studies that use specialized iPhone apps, built with software Apple Inc. developed to help turn the...

  • UPDATE 1-Bellerophon's heart device fails study Monday, 27 Jul 2015 | 7:31 AM ET

    July 27- Bellerophon Therapeutics Inc said its implantable heart device failed to prevent heart failure in patients in a large study, casting doubts over an approval for the device in Europe. The device, Bioabsorbable Cardiac Matrix, was licensed to Bellerophon by BioLineRx Ltd in 2009.. BioLineRx's U.S.-listed shares fell 18 percent to $1.76 in premarket...

  • Bellerophon's heart device fails study Monday, 27 Jul 2015 | 6:36 AM ET

    July 27- Bellerophon Therapeutics Inc said its implantable heart device failed to prevent heart failure in patients in a large study, casting doubts over an approval for the device in Europe. The device, Bioabsorbable Cardiac Matrix, was tested in 303 patients who had already suffered a heart attack. The device was licensed to Bellerophon by BioLineRx Ltd in...

  • TRENTON, N.J.— An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options— all much more effective but extremely costly— for patients with the liver-destroying virus. Daklinza, developed by New York- based Bristol-Myers Squibb Co., is the first drug approved to...

  • July 24- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections. Technivie, includes the same cocktail of drugs that...

  • WASHINGTON, July 24- The U.S. Food and Drug Administration approved a potent new cholesterol-lowering drug from Sanofi SA and Regeneron Pharmaceuticals Inc on Friday but limited its approved use to patients with a hereditary form of the condition and those with cardiovascular disease. The FDA ruling came just hours after European regulators recommended...